Participate in Research

Research studies help find new methods for diagnosing, treating, managing, and preventing Crohn's disease and ulcerative colitis. Even the most promising scientific findings must first be proven to be safe and effective before they can be used in the management of inflammatory bowel disease (IBD).

If you are interested in learning more about participating in a research study or clinical trial, speak with your doctor.

Participate in Research icons

Active studies recruiting participants: 

  • Persons from across Canada are being invited to participate in the IMAGINE research study. The IMAGINE Network is investigating the interactions between inflammation, microbiome, diet and mental health in patient with IBD (Crohn’s disease or ulcerative colitis) or irritable bowel syndrome (IBS). IMAGINE is also studying whether new therapies (fecal transplants, diet, probiotics, cognitive behaviour therapy) have the potential to transform the management of IBD and IBS and their associated mental health issues.
    You may be eligible to participate in this study if you have been diagnosed by your physician with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn’s disease, or are a healthy individual without gastrointestinal symptoms. Visit for more information and to find a recruitment site near you.
  • The PedCRaFT (peditric Crohn’s Disease Fecal Microbiota Transplant) Trial is the first Health Canada approved randomized-control fecal transplant study for Pediatric Crohn’s disease in Canada.

    Study involves:
    i) Colonoscopy-initial baseline colonoscopy under anesthesia, where you will receive an infusion via colonoscopy of either healthy bacteria or a normal saline placebo.
    ii) Oral Capsule-2x week for 6 weeks, you will receive pill capsules that may be taken at home. Pill capsules will either contain healthy bacteria or sugar-containing placebo.

    We will ask you to provide:
    1.) Bloodwork
    2.) Urine Samples
    3.) Stool samples
    4.) Complete a 6-Question survey

    This study has been approved by the Hamilton Integrated Research Ethics Board.

    Who is eligible?
    Children between ages 3 to 17 diagnosed with Crohn’s disease or IBD-U favouring Crohn’s disease (as identified by your physician) on a stable therapy (no major changes to medication within the last four weeks).

    Principal Investigator: Dr Nikhil Pai, Division of Pediatric GI and Nutrition McMaster Children's Hospital
    To participate, please contact:
    Lee Hill, BSc (Med)(Hons), PhD (c)  
    The PediCRaFT Research Team at
    Phone: 514-443-8488
  • The Family Health Lab at University of Saskatchewan is currently conducting an online study looking at the relationship between emotions and IBD-related symptoms in teens with inflammatory bowel disease (IBD).

    Who is eligible to participate?
    Teens ages 14 to 18 who have been diagnosed with ulcerative colitis or Crohn's disease who has a parent that will provide consent for the teen to participate.

    To register for the study or for more information, please contact:

    Lana McAleer
    Phone: 306-966-5616

    Teens and parents able to participate are eligible to enter a draw to win one of three $50 gift cards.
  • Become an advocate for Canadian students living with IBD!
    The purpose research study is to understand how young Canadians with inflammatory bowel disease (IBD) maintain well-being and achieve academic success while pursuing post-secondary education. The researcher is interested in learning about your personal experiences and coping strategies in a one-on-one interview (approximately 2 hours).

    Who is eligible to participate? 
    Must be between the ages of 18-26, living with IBD, and currently enrolled in, or recently graduated from, post-secondary education. Recruiting 15-20 participants. 

    This study is being conducted as part of my thesis dissertation under the supervision of Principal investigator, Dr. Satsuki Kawano. This project has been reviewed by the Research Ethics Board for compliance with federal guidelines for research involving human participants [REB# 19-05-005]. 

    To register for the study or for more information, please contact: 

    Jenna LeClair, Graduate Student, Department of Sociology and Anthropology, University of Guelph 
  • This research is looking at the experiences of young women living with an ostomy as a result of Inflammatory Bowel Disease, looking at the decision-making process up to surgery and actual lived experience of having an ostomy. If you are interested in participating an interview will be arranged at your convenience and take approximately one to two hours.  

    Who is eligible?  
    Young women between 19-25 living with an ostomy for any length of time.

    Interested in participating? Contact Ashley Cark 
    Phone 1-250-812-8908

    Researcher: Ashley Clark MA, University of Victoria, Social Dimensions of Health.
    Supervisor/Primary Investigator: Dr. Andre Smith, Associate Professor, Sociology, University of Victoria.
  • The human body contains ten bacterial cells for every human cell. This vast, largely unexplored bacterial community, known as the microbiome, has been linked to gastrointestinal health and disease. In the case of inflammatory bowel disease (IBD), it is thought that the immune system may be responding inappropriately to the microbiome. Therefore, it has been hypothesized that changing the microbiome may be an effective treatment for IBD. One way to accomplish this is using Fecal Microbiota Transplantation (FMT), an innovative investigational treatment that has proven effective in the treatment of C. difficile infection.

    The purpose of this study is to determine whether FMT is similarly safe and effective in the treatment of mild-to-moderate Crohn’s disease. During FMT, a fecal preparation from a carefully screened, healthy stool donor is transplanted into the colon of the patient. There are multiple routes of administration. We will use both in this study. 

    Patients will receive a total of eight FMT/placebo treatments in the study. Patients receiving FMT will be assigned a single donor. The first will be given by colonoscopy at week zero, followed by seven others given by capsules taken by mouth each week. At week eight, patients are unblinded and a follow up colonoscopy is performed. Patients who were initially randomized to placebo can go on to have FMT in the open label phase of the study.
    Who is eligible to participate?
    Patients with mild to moderate Crohn’s disease
    Recruiting 126 patients at three Canadian centres (Edmonton, Calgary and Hamilton)
    To register for this study or for more information, please contact:

    Edmonton Contacts
    Dr. Dina Kao:
    Dr. Gina Vavek:
    Phone: 780-492-5313
    Calgary Contacts
    Dr. Humberto Jijon:
    Gurmeet Bindra:
    Phone: 403-210-7013 or 403-399-9790
    Hamilton Contact
    Melanie Wolfe:

Studies listed here have been submitted to Crohn’s and Colitis Canada by researchers and their teams. This means this list does not include all studies happening related to Crohn’s disease and ulcerative colitis. Below you will find two other websites that list more studies that people with Crohn’s and colitis in Canada may be eligible to participate in. 

You may search for clinical trials through the following sites:


Crohn’s and Colitis Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest